Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is poised for growth as a leader in blood-based organ transplant testing, with a strong market presence and ongoing innovations. The company's recent acquisition and launch of AlloHeme, targeting a significant TAM, indicate a strategic expansion beyond transplant testing. While potential risks include regulatory and operational challenges and competition, the company's financial performance and product advancements suggest a positive outlook for future success.

Bears say

CareDx is a precision medicine company that offers testing services, products, and digital solutions for transplant patients. While the company has provided LT financial targets, its success will rely on its ability to commercialize additional diagnostic solutions, which may take years to develop and gain acceptance. Additionally, potential LCD impacts and uncertain long-term plans also raise concerns about the company's future growth and profitability.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.